Royalty PharmaRPRX
Recorded

Royalty Pharma UBS Global Biopharma Conference 2026

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration31 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Ash VermaAnalyst

Okay. Good day, everybody. Thank you so much for joining. Welcome back to the next session at the UBS Global Biopharma Conference in London. I am really excited to have Royalty Pharma here, and we have Chris Hite, who is the Chairman of Partnering and Investment, and Greg Butz, who is EVP of Partnering. Thank you, gentlemen, for joining us.

Ash VermaAnalyst

Thank you. Thanks. Yeah, thanks.

Ash VermaAnalyst

Kind of very unique story and very well understood by investors, by some investors, I would say. But always good to start with some level of background, just so that people are aware. If you can just hit a couple of highlights on some of the key takeaways from the third quarter earnings as well, we can start there.

Chris HiteChairman of Partnering and Investment

Sure. Well, thanks again for having us. We really appreciate the opportunity. It is a great conference. To start with maybe just background on Royalty Pharma, the company is 30 years old. We celebrated our 30th anniversary recently. Really created with the idea to buy existing royalty streams from hospitals, foundations, universities, way back when, and we still do that. The company went public in 2020. We are investment-grade rated. Capital deployment, publicly stated goals of $2 billion-$2.5 billion a year. We still buy existing royalty streams, but we have really sort of morphed the business and grown the business by co-investing with biotech and pharma to help them fund their R&D programs, provide them capital to launch their drugs, and we call those synthetic royalties. They are not existing royalty streams, but we create new royalties through that process of funding R&D and helping them launch the drugs.

Chris HiteChairman of Partnering and Investment

The business has grown tremendously. Our opportunity set has grown tremendously. Last year, we looked at 480 opportunities. I think we did about seven deals for about $4.7 billion in announced transaction value. It is a hugely exciting growth opportunity business. That is the quick history of the company. Exciting third quarter results. We just announced another beat on the earnings and raise. Some of our exciting products that really delivered on the growth for the quarter were Tremfya, which is J&J's product in IBD, huge growth in the quarter. Another product called VORANIGO, which is marketed by Servier, really strong grower. Then some of our other products that have been consistent growers, like EVRYSDI, another strong quarter. So, another great quarter, beat and raise. We are super excited. Good.

Ash VermaAnalyst

Awesome. So, seven out of 480 deals that you looked at, you said?

Chris HiteChairman of Partnering and Investment

That is very nice. That was in 2025, yeah.

Chris HiteChairman of Partnering and Investment

Yeah. 480 initial reviews. Yeah.

Chris HiteChairman of Partnering and Investment

Opportunities. Great. Okay. Busy. We were busy, and we are busier, if that could be possible, this year.

Ash VermaAnalyst

Yeah. Yeah, I guess it is interesting. More and more, this has become a mainstream option, or maybe at least the way that investors look at it, that the growth of royalty space has been spectacular. And so there has been a secular growth trend that has been happening here. I guess from your vantage point, what do you think has been driving that overall?

Chris HiteChairman of Partnering and Investment

I think it is a lot of factors that have transformed this opportunity set. One is the financing itself is extraordinarily attractive. So, for a biotech company that is not profitable, they have a couple different options. Let us take the Revolution Medicines deal that we did last year, where we provided Revolution Medicines up to $2 billion in financing to help them advance their pipeline and get ready to launch daraxonrasib. And a company like that has options to fund itself, right? It was probably around an $8 billion market cap company. A lot of excitement around the possibility of daraxonrasib reading out positively. They could certainly, as most biotech companies do, go to the equity capital markets and fund their pipeline through equity offerings or convertible bond offerings, or they could partner. They could partner in the U.S. or ex-U.S.

Chris HiteChairman of Partnering and Investment

That's what most biotech companies do, and that provides capital. The reason why synthetic royalties are very attractive to companies like Revolution Medicines is they can avoid partnering their asset. When you think about the cost of capital for a synthetic royalty versus raising equity capital, it's much more attractive. Think about how that stock has performed since the time of that deal, and when you calculate if they had raised the money we gave them in the equity market, and seeing how its stock has performed, that cost of capital far exceeds what they were able to achieve through our deal with them. There's a lot of flexibility when you partner with us. We're a passive partner. We're not active, so we're not asking for JDCs or JSCs. There's no sort of covenants that restrict your ability to do things.

Chris HiteChairman of Partnering and Investment

You're not giving away regions to other partners. Just a lot of attractiveness. If you're a biotech company that's thinking about raising capital, I think those features have become prevalent in the industry now. I joined Royalty Pharma at the beginning of 2020. Greg just recently joined. I can tell you, we were both bankers, and when I left banking in 2019, effectively, we weren't going and pitching synthetic royalties to biotech CFOs. You didn't really do that. You went to the meetings with the capital markets person, you talked about equity and converts. I think now the banking community understands the attractiveness of working with a company like Royalty Pharma for all the reasons I just mentioned, and so it's become part of the ecosystem, of the financing ecosystem.

Chris HiteChairman of Partnering and Investment

We did a survey last year with Deloitte, or Deloitte did a survey, where they surveyed over 100 biotech CEOs and CFOs, and it really came through that survey how aware and how willing to use synthetic royalties to finance their companies they are in the industry now. It's really transformed. It's really completely different than it was even when I joined the company seven years ago.

Greg ButzEVP of Partnering

Ash, I'd add one more point, which is, Chris talked about the evolution of what we've done. Monetizing passive royalties from academic institutions, from universities, that really was the foundation of Royalty Pharma at inception. That will continue. Then the creation of the synthetic royalty, which we did, which now has become a very credible option for biotech companies to raise capital as an alternative to equity or convertible debt. Now the third leg of that evolution has been the co-funding deals that we're doing with bigger biotech, big pharma, and that I think will, looking ahead, be an even bigger portion of our kind of growth profile over time. You've seen obviously some recent examples of that.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day